Does Medicare or Medicaid cover GLP-1s for weight loss?

The Medicare wall and its real doors. Since 2006, Part D has statutorily excluded “weight loss” drugs — a 20-year-old rule colliding with modern medicine, with repeal perennially proposed and not yet law. The doors that exist run through other FDA-approved indications of the same molecules: - Type 2 diabetes → Ozempic, Mounjaro, Rybelsus covered as diabetes drugs (formulary rules apply). - Cardiovascular risk reduction → after SELECT, Wegovy carries a CV indication; Medicare plans cover it for that indication — documented cardiovascular disease plus overweight/obesity, not weight loss per se. - Obstructive sleep apnea → Zepbound’s OSA indication opens the same kind of door; a sleep study becomes a coverage document. Practical translation: on Medicare, your path is a precise diagnosis code and a prescriber who writes for the covered indication. “Wegovy for weight” is denied; “Wegovy for established CVD risk reduction” can clear. Also note: manufacturer savings cards are legally barred for Medicare patients — direct-pharmacy cash prices become the fallback. Medicaid: a 50-state patchwork. States may cover anti-obesity drugs and a growing minority do (with PA requirements); most still don’t, and several that did have trimmed coverage under budget pressure. Diabetes-indication coverage is near-universal. Check your state’s preferred drug list, or have the prescriber’s office run a test claim — coverage changes year to year. If both fail: the cash routes ($199–$499/month tiers) are the honest fallback, and for the diabetes-adjacent, getting properly tested matters — an actual T2D or OSA diagnosis isn’t gaming the system, it’s documenting disease that obesity makes likely and that changes the coverage math entirely.